Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Synthomer PLC is a specialty chemical company. It is engaged in developing, manufacturing and marketing of aqueous polymers used in use in coatings, building products, gloves, carpets, paper, ...

Synthomer PLC is a specialty chemicals company. It supplies a variety of chemicals including latex and adhesives, which are used in a wide range of markets such as construction, coatings, textiles, ...

Based on 6 Wall Street analysts offering 12 month price targets forSynthomer PLC - Dist in the last 3 months. Based on 6 analysts giving stock ratings to Synthomer PLC - Dist in the past 3 months.

First-in-human data with investigational formulation of SYNT-101 establish preliminary safety, tolerability and efficacy markers, including modulation of hunger hormones Preclinical weight loss data ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as ...

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

肥胖已成为全球性健康危机，据世界卫生组织统计，近年来全球肥胖率不断攀升，每年因肥胖相关并发症导致的死亡人数众多。 目前，尽管胰高血糖素样肽-1（GLP-1）受体激动剂等药物在肥胖治疗领域取得了重大突破，但此类药物往往伴随着如胃肠道副作用 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Syntis Bio, Inc. (Syntis), a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes and rare diseases, today announced positive preclinical and first-in-human ...

BOSTON--(BUSINESS WIRE)--Syntis Bio, Inc. (Syntis), a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes and rare diseases, today announced positive ...